You are here

New Carriers Used as Adjuvants for Controlled HIV Immunogen Delivery into Targeted Antigen Presenting Cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N93019C00013
Agency Tracking Number: N43AI190013
Amount: $600,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: N/A
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4878 Ronson CT STE K, SAN DIEGO, CA, 92111-1806
DUNS: 159070825
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Philippe Saint-Cricq-Riviere
 (858) 565-4227
Business Contact
 Philippe Saint-Cricq-Riviere
Phone: (858) 565-4227
Research Institution
Despite the global impacts of HIV on human healthwith an estimatedmillion new cases each year andmillion people living with HIVan effective vaccine has not been developedThere are many challenges for HIV vaccine development including the virus s rapidly changing surface immunogens and the early integration of the virus into the host s genomeTo overcome these challengesa mesoporous silica adjuvant particle will be developed that can be targeted to antigen presenting cells to facilitate particle uptakeThe pores of the particle will be loaded with both mRNA and agonists to elicit a strong immune responseThe particles will be capped with a pH sensitive polymer that will release the pore contents on exposure to the lower pH of the antigen presenting cell endosomeswhile protecting the contents prior to pH activationThe proposed nanocarrier addresses many of the prior deficiencies of other delivery strategies and has the potential to enable the development of a highly efficacious HIV vaccine

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government